Show simple item record

dc.contributor.authorÇiftçiler, Rafiye
dc.contributor.authorÖzenirler, Seren
dc.contributor.authorAtak Yücel, Ayşegül
dc.contributor.authorCengiz, Mustafa
dc.contributor.authorErkan, Gülbanu
dc.contributor.authorBüyükdemirci, Erkan
dc.contributor.authorSönmez, Cemile
dc.contributor.authorYılmaz Esendağlı, Güldal
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:57:41Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:57:41Z
dc.date.issued2017en_US
dc.identifier.citationÇiftçiler, R., Özenirler, S., Atak Yücel, A., Cengiz, M., Erkan, G., Büyükdemirci, E. … Yılmaz Esendağlı, G. (2017). The importance of serum biglycan levels as a fibrosis marker in patients with chronic hepatitis B. Journal of Clinical Laboratory Analysis, 31(5). https://dx.doi.org/10.1002/jcla.22109en_US
dc.identifier.issn0887-8013
dc.identifier.issn1098-2825
dc.identifier.urihttps://dx.doi.org/10.1002/jcla.22109
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3029
dc.descriptionWOS: 000411716300040en_US
dc.descriptionPubMed ID: 27925300en_US
dc.description.abstractBackgroundLiver biopsy is recommended in the majority of patients with chronic viral hepatitis for fibrosis evaluation. Because of the potential risks of liver biopsy, many studies related to non-invasive biomarkers of hepatic fibrosis have been performed. We aimed to assess the diagnostic value of serum biglycan as a non-invasive fibrosis marker in chronic hepatitis B patients. MethodsThis study included 120 patients with biopsy-proven hepatitis B patients and 60 healthy controls. Fibrosis stage and necroinflammatory activity were assessed in liver biopsy specimens. Biglycan level was measured using an ELISA assay. ResultsSerum biglycan levels of chronic hepatitis B patients were found to be significantly higher than those of healthy controls (337.3363.0pg/mL vs 189.1 +/- 61.9pg/mL, respectively, P<.001). There was a statistically significant positive correlation between serum biglycan level and fibrosis stage (P=.004; r=.213). Besides, a statistically significant positive correlation was found between serum biglycan level and necroinflammatory activity (P<.001; r=.271). The AUROC of BGN levels was 0.702 for fibrosis stage, differentiating patients from healthy controls with statistical significance (P<.001). The AUROC of BGN levels was 0.632 for necroinflammatory activity score, differentiating patients from healthy controls with statistical significance (P=.004). ConclusionsSerum biglycan might be used as a non-invasive marker of liver fibrosis. Further studies are needed to evaluate the usefulness of this marker.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiglycanen_US
dc.subjectChronic Hepatitis Ben_US
dc.subjectLiver Biopsyen_US
dc.subjectLiver Fibrosisen_US
dc.subjectNon-Invasive Markeren_US
dc.titleThe importance of serum biglycan levels as a fibrosis marker in patients with chronic hepatitis Ben_US
dc.typearticleen_US
dc.relation.journalJournal of Clinical Laboratory Analysisen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0002-1824-9934en_US
dc.identifier.volume31en_US
dc.identifier.issue5en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1002/jcla.22109en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record